Home > > > Report Detail

Global Duchenne Muscular Dystrophy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Publisher Name :
Date: 22-Sep-2022
No. of pages: 107
Inquire Before Buying

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Highlights

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, the global Duchenne Muscular Dystrophy market is projected to reach US$ 13540 million by 2028 from an estimated US$ 1644 million in 2022, at a CAGR of 42.1% during 2023 and 2028.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.

North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.

In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy.

The Duchenne Muscular Dystrophy market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Duchenne Muscular Dystrophy market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Duchenne Muscular Dystrophy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

- Sarepta Therapeutics

- PTC Therapeutics

- Pfizer

- Bristol-Myers Squibb

- Italfarmaco

- Santhera Pharmaceuticals

Product Type Insights

Global markets are presented by Duchenne Muscular Dystrophy type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Duchenne Muscular Dystrophy are procured by the manufacturers.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Duchenne Muscular Dystrophy Segment by Type

- Exondys 51

- Emflaza

- Translarna

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).

This report also outlines the market trends of each segment and consumer behaviors impacting the Duchenne Muscular Dystrophy market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Duchenne Muscular Dystrophy market.

Duchenne Muscular Dystrophy Segment by Application

- Hospitals

- Clinics

- Home Care

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- - Nordic Countries

- - Benelux

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Southeast Asia

- - Australia

- - Rest of Asia-Pacific

- Latin America

- - Mexico

- - Brazil

- - Argentina

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of Middle East & Africa

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Duchenne Muscular Dystrophy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Duchenne Muscular Dystrophy industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution

Global Duchenne Muscular Dystrophy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Table of Contents
1 Study Coverage
1.1 Duchenne Muscular Dystrophy Product Introduction
1.2 Market by Type
1.2.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Exondys 51
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application (2017 VS 2021 VS 2028)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Duchenne Muscular Dystrophy Market Size Estimates and Forecasts
2.1.1 Global Duchenne Muscular Dystrophy Revenue 2017-2028
2.1.2 Global Duchenne Muscular Dystrophy Sales 2017-2028
2.2 Duchenne Muscular Dystrophy Market Size by Region: 2022 Versus 2028
2.3 Duchenne Muscular Dystrophy Sales by Region (2017-2028)
2.3.1 Global Duchenne Muscular Dystrophy Sales by Region: 2017-2022
2.3.2 Global Duchenne Muscular Dystrophy Sales Forecast by Region (2023-2028)
2.3.3 Global Duchenne Muscular Dystrophy Sales Market Share by Region (2017-2028)
2.4 Duchenne Muscular Dystrophy Market Estimates and Projections by Region (2023-2028)
2.4.1 Global Duchenne Muscular Dystrophy Revenue by Region: 2017-2022
2.4.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Region (2023-2028)
2.4.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2017-2028)
3 Global Duchenne Muscular Dystrophy by Manufacturers
3.1 Global Top Duchenne Muscular Dystrophy Manufacturers by Sales
3.1.1 Global Duchenne Muscular Dystrophy Sales by Manufacturer (2017-2022)
3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturer (2017-2022)
3.2 Global Top Duchenne Muscular Dystrophy Manufacturers by Revenue
3.2.1 Global Duchenne Muscular Dystrophy Revenue by Manufacturer (2017-2022)
3.2.2 Global Duchenne Muscular Dystrophy Revenue Share by Manufacturer (2017-2022)
3.3 Global Duchenne Muscular Dystrophy Price by Manufacturer (2017-2022)
3.4 Competitive Landscape
3.4.1 Key Duchenne Muscular Dystrophy Manufacturers Covered: Ranking by Revenue
3.4.2 Global Duchenne Muscular Dystrophy Market Concentration Ratio (CR5 and HHI) & (2017-2022)
3.4.3 Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Duchenne Muscular Dystrophy Manufacturing Base Distribution, Product Type
3.5.1 Duchenne Muscular Dystrophy Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Duchenne Muscular Dystrophy Product Type
3.5.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Sarepta Therapeutics
4.1.1 Sarepta Therapeutics Corporation Information
4.1.2 Sarepta Therapeutics Description, Business Overview
4.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Products Offered
4.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2017-2022)
4.1.5 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Product in 2021
4.1.6 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Application in 2021
4.1.7 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Geographic Area in 2021
4.1.8 Sarepta Therapeutics Recent Developments
4.2 PTC Therapeutics
4.2.1 PTC Therapeutics Corporation Information
4.2.2 PTC Therapeutics Description, Business Overview
4.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Products Offered
4.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2017-2022)
4.2.5 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Product in 2021
4.2.6 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Application in 2021
4.2.7 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Geographic Area in 2021
4.2.8 PTC Therapeutics Recent Developments
4.3 Pfizer
4.3.1 Pfizer Corporation Information
4.3.2 Pfizer Description, Business Overview
4.3.3 Pfizer Duchenne Muscular Dystrophy Products Offered
4.3.4 Pfizer Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2017-2022)
4.3.5 Pfizer Duchenne Muscular Dystrophy Sales by Product in 2021
4.3.6 Pfizer Duchenne Muscular Dystrophy Sales by Application in 2021
4.3.7 Pfizer Duchenne Muscular Dystrophy Sales by Geographic Area in 2021
4.3.8 Pfizer Recent Developments
4.4 Bristol-Myers Squibb
4.4.1 Bristol-Myers Squibb Corporation Information
4.4.2 Bristol-Myers Squibb Description, Business Overview
4.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Products Offered
4.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2017-2022)
4.4.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Product in 2021
4.4.6 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Application in 2021
4.4.7 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Geographic Area in 2021
4.4.8 Bristol-Myers Squibb Recent Developments
4.5 Italfarmaco
4.5.1 Italfarmaco Corporation Information
4.5.2 Italfarmaco Description, Business Overview
4.5.3 Italfarmaco Duchenne Muscular Dystrophy Products Offered
4.5.4 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2017-2022)
4.5.5 Italfarmaco Duchenne Muscular Dystrophy Sales by Product in 2021
4.5.6 Italfarmaco Duchenne Muscular Dystrophy Sales by Application in 2021
4.5.7 Italfarmaco Duchenne Muscular Dystrophy Sales by Geographic Area in 2021
4.5.8 Italfarmaco Recent Developments
4.6 Santhera Pharmaceuticals
4.6.1 Santhera Pharmaceuticals Corporation Information
4.6.2 Santhera Pharmaceuticals Description, Business Overview
4.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Products Offered
4.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2017-2022)
4.6.5 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Product in 2021
4.6.6 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Application in 2021
4.6.7 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Geographic Area in 2021
4.6.8 Santhera Pharmaceuticals Recent Development
5 Breakdown Data by Type
5.1 Global Duchenne Muscular Dystrophy Sales by Type (2017-2028)
5.1.1 Global Duchenne Muscular Dystrophy Sales by Type (2017-2022)
5.1.2 Global Duchenne Muscular Dystrophy Sales Forecast by Type (2023-2028)
5.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2028)
5.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Type (2017-2028)
5.2.1 Global Duchenne Muscular Dystrophy Revenue by Type (2017-2022)
5.2.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Type (2023-2028)
5.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2017-2028)
5.3 Duchenne Muscular Dystrophy Average Selling Price (ASP) by Type (2017-2028)
6 Breakdown Data by Application
6.1 Global Duchenne Muscular Dystrophy Sales by Application (2017-2028)
6.1.1 Global Duchenne Muscular Dystrophy Sales by Application (2017-2022)
6.1.2 Global Duchenne Muscular Dystrophy Sales Forecast by Application (2023-2028)
6.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2028)
6.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Application (2017-2028)
6.2.1 Global Duchenne Muscular Dystrophy Revenue by Application (2017-2022)
6.2.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Application (2023-2028)
6.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2017-2028)
6.3 Duchenne Muscular Dystrophy Average Selling Price (ASP) by Application (2017-2028)
7 North America
7.1 North America Duchenne Muscular Dystrophy Market Size YoY Growth 2017-2028
7.2 North America Duchenne Muscular Dystrophy Market Facts & Figures by Country
7.2.1 North America Duchenne Muscular Dystrophy Sales by Country (2017-2028)
7.2.2 North America Duchenne Muscular Dystrophy Revenue by Country (2017-2028)
7.3 North America Duchenne Muscular Dystrophy Sales by Type
7.4 North America Duchenne Muscular Dystrophy Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Market Size YoY Growth 2017-2028
8.2 Asia-Pacific Duchenne Muscular Dystrophy Market Facts & Figures by Region
8.2.1 Asia-Pacific Duchenne Muscular Dystrophy Sales by Region (2017-2028)
8.2.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue by Region (2017-2028)
8.3 Asia-Pacific Duchenne Muscular Dystrophy Sales by Type
8.4 Asia-Pacific Duchenne Muscular Dystrophy Sales by Application
9 Europe
9.1 Europe Duchenne Muscular Dystrophy Market Size YoY Growth 2017-2028
9.2 Europe Duchenne Muscular Dystrophy Market Facts & Figures by Country
9.2.1 Europe Duchenne Muscular Dystrophy Sales by Country (2017-2028)
9.2.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2017-2028)
9.3 Europe Duchenne Muscular Dystrophy Sales by Type
9.4 Europe Duchenne Muscular Dystrophy Sales by Application
10 Latin America
10.1 Latin America Duchenne Muscular Dystrophy Market Size YoY Growth 2017-2028
10.2 Latin America Duchenne Muscular Dystrophy Market Facts & Figures by Country
10.2.1 Latin America Duchenne Muscular Dystrophy Sales by Country (2017-2028)
10.2.2 Latin America Duchenne Muscular Dystrophy Revenue by Country (2017-2028)
10.3 Latin America Duchenne Muscular Dystrophy Sales by Type
10.4 Latin America Duchenne Muscular Dystrophy Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size YoY Growth 2017-2028
11.2 Middle East and Africa Duchenne Muscular Dystrophy Market Facts & Figures by Country
11.2.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2017-2028)
11.2.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2017-2028)
11.3 Middle East and Africa Duchenne Muscular Dystrophy Sales by Type
11.4 Middle East and Africa Duchenne Muscular Dystrophy Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Duchenne Muscular Dystrophy Supply Chain Analysis
12.2 Duchenne Muscular Dystrophy Key Raw Materials and Upstream Suppliers
12.3 Duchenne Muscular Dystrophy Clients Analysis
12.4 Duchenne Muscular Dystrophy Sales Channel and Sales Model Analysis
12.4.1 Duchenne Muscular Dystrophy Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Duchenne Muscular Dystrophy Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Duchenne Muscular Dystrophy Distributors
13 Market Dynamics
13.1 Duchenne Muscular Dystrophy Industry Trends
13.2 Duchenne Muscular Dystrophy Market Drivers
13.3 Duchenne Muscular Dystrophy Market Challenges
13.4 Duchenne Muscular Dystrophy Market Restraints
13.5 Porter's Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Major Manufacturers of Exondys 51
Table 3. Major Manufacturers of Emflaza
Table 4. Major Manufacturers of Translarna
Table 5. Global Duchenne Muscular Dystrophy Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Duchenne Muscular Dystrophy Market Size by Region (US$ Million): 2021 VS 2022 VS 2028
Table 7. Global Duchenne Muscular Dystrophy Sales by Region (2017-2022) & (K Doses)
Table 8. Global Duchenne Muscular Dystrophy Sales Forecast by Region (2023-2028) & (K Doses)
Table 9. Global Duchenne Muscular Dystrophy Revenue by Region (2017-2022) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 11. Global Duchenne Muscular Dystrophy Sales by Manufacturer (2017-2022) & (K Doses)
Table 12. Global Duchenne Muscular Dystrophy Sales Share by Manufacturer (2017-2022)
Table 13. Duchenne Muscular Dystrophy Revenue by Manufacturer (2017-2022) & (US$ Million)
Table 14. Duchenne Muscular Dystrophy Revenue Share by Manufacturer (2017-2022)
Table 15. Key Manufacturers Duchenne Muscular Dystrophy Price (2017-2022) & (USD/Dose)
Table 16. Ranking of Global Top Duchenne Muscular Dystrophy Manufacturers by Revenue (US$ Million) in 2021
Table 17. Global Duchenne Muscular Dystrophy Manufacturers Market Concentration Ratio (CR5 and HHI) & (2017-2022)
Table 18. Global Duchenne Muscular Dystrophy by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2021)
Table 19. Duchenne Muscular Dystrophy Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Duchenne Muscular Dystrophy Product Type
Table 21. Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Sarepta Therapeutics Corporation Information
Table 24. Sarepta Therapeutics Description and Business Overview
Table 25. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 26. Sarepta Therapeutics Duchenne Muscular Dystrophy Product
Table 27. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Product in 2021
Table 28. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Application in 2021
Table 29. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2021
Table 30. Sarepta Therapeutics Recent Development
Table 31. PTC Therapeutics Corporation Information
Table 32. PTC Therapeutics Description and Business Overview
Table 33. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 34. PTC Therapeutics Duchenne Muscular Dystrophy Product
Table 35. PTC Therapeutics Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Product in 2021
Table 36. PTC Therapeutics Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Application in 2021
Table 37. PTC Therapeutics Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2021
Table 38. PTC Therapeutics Recent Development
Table 39. Pfizer Corporation Information
Table 40. Pfizer Description and Business Overview
Table 41. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 42. Pfizer Duchenne Muscular Dystrophy Product
Table 43. Pfizer Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Product in 2021
Table 44. Pfizer Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Application in 2021
Table 45. Pfizer Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2021
Table 46. Pfizer Recent Development
Table 47. Bristol-Myers Squibb Corporation Information
Table 48. Bristol-Myers Squibb Description and Business Overview
Table 49. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 50. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product
Table 51. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Product in 2021
Table 52. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Application in 2021
Table 53. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2021
Table 54. Bristol-Myers Squibb Recent Development
Table 55. Italfarmaco Corporation Information
Table 56. Italfarmaco Description and Business Overview
Table 57. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 58. Italfarmaco Duchenne Muscular Dystrophy Product
Table 59. Italfarmaco Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Product in 2021
Table 60. Italfarmaco Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Application in 2021
Table 61. Italfarmaco Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2021
Table 62. Italfarmaco Recent Development
Table 63. Santhera Pharmaceuticals Corporation Information
Table 64. Santhera Pharmaceuticals Description and Business Overview
Table 65. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 66. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product
Table 67. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Product in 2021
Table 68. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Application in 2021
Table 69. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2021
Table 70. Global Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 71. Global Duchenne Muscular Dystrophy Sales Forecast by Type (2023-2028) & (K Doses)
Table 72. Global Duchenne Muscular Dystrophy Revenue by Type (2017-2022) & (US$ Million)
Table 73. Global Duchenne Muscular Dystrophy Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 74. Global Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 75. Global Duchenne Muscular Dystrophy Sales Forecast by Application (2023-2028) & (K Doses)
Table 76. Global Duchenne Muscular Dystrophy Revenue by Application (2017-2022) & (US$ Million)
Table 77. Global Duchenne Muscular Dystrophy Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 78. North America Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
Table 79. North America Duchenne Muscular Dystrophy Sales by Country (2023-2028) & (K Doses)
Table 80. North America Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & (US$ Million)
Table 81. North America Duchenne Muscular Dystrophy Revenue by Country (2023-2028) & (US$ Million)
Table 82. North America Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 83. North America Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 84. Asia-Pacific Duchenne Muscular Dystrophy Sales by Region (2017-2022) & (K Doses)
Table 85. Asia-Pacific Duchenne Muscular Dystrophy Sales by Region (2023-2028) & (K Doses)
Table 86. Asia-Pacific Duchenne Muscular Dystrophy Revenue by Region (2017-2028) & (US$ Million)
Table 87. Asia-Pacific Duchenne Muscular Dystrophy Revenue by Region (2023-2028) & (US$ Million)
Table 88. Asia-Pacific Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 89. Asia-Pacific Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 90. Europe Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
Table 91. Europe Duchenne Muscular Dystrophy Sales by Country (2023-2028) & (K Doses)
Table 92. Europe Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & (US$ Million)
Table 93. Europe Duchenne Muscular Dystrophy Revenue by Country (2023-2028) & (US$ Million)
Table 94. Europe Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 95. Europe Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 96. Latin America Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
Table 97. Latin America Duchenne Muscular Dystrophy Sales by Country (2023-2028) & (K Doses)
Table 98. Latin America Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & (US$ Million)
Table 99. Latin America Duchenne Muscular Dystrophy Revenue by Country (2023-2028) & (US$ Million)
Table 100. Latin America Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 101. Latin America Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 102. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2017-2022) & (K Doses)
Table 103. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2023-2028) & (K Doses)
Table 104. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2023-2028) & (US$ Million)
Table 106. Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2017-2022) & (K Doses)
Table 107. Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2017-2022) & (K Doses)
Table 108. Duchenne Muscular Dystrophy Key Raw Materials, Industry Status and Trend
Table 109. Duchenne Muscular Dystrophy Key Raw Materials and Upstream Suppliers
Table 110. Duchenne Muscular Dystrophy Clients Status and Trend
Table 111. Duchenne Muscular Dystrophy Typical Clients
Table 112. Duchenne Muscular Dystrophy Distributors
Table 113. Duchenne Muscular Dystrophy Market Trends
Table 114. Duchenne Muscular Dystrophy Market Drivers
Table 115. Duchenne Muscular Dystrophy Market Challenges
Table 116. Duchenne Muscular Dystrophy Market Restraints
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Duchenne Muscular Dystrophy Product Picture
Figure 2. Global Duchenne Muscular Dystrophy Sales Market Share by Type in 2021 & 2028
Figure 3. Exondys 51 Product Picture
Figure 4. Emflaza Product Picture
Figure 5. Translarna Product Picture
Figure 6. Global Duchenne Muscular Dystrophy Sales Market Share by Application in 2021 & 2028
Figure 7. Hospitals Examples
Figure 8. Clinics Examples
Figure 9. Home Care Examples
Figure 10. Duchenne Muscular Dystrophy Report Years Considered
Figure 11. Global Duchenne Muscular Dystrophy Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Duchenne Muscular Dystrophy Market Size 2017-2028 (US$ Million)
Figure 13. Global Duchenne Muscular Dystrophy Sales 2017-2028 (K Doses)
Figure 14. Global Duchenne Muscular Dystrophy Market Size Market Share by Region: 2022 Versus 2028
Figure 15. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Region (2017-2028)
Figure 16. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2017-2028)
Figure 17. Global Duchenne Muscular Dystrophy Sales Share by Manufacturer in 2021
Figure 18. Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 19. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Type (2017-2028)
Figure 20. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type (2017-2028)
Figure 21. Duchenne Muscular Dystrophy Average Selling Price (ASP) by Type (2017-2022) & (USD/Dose)
Figure 22. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Application (2017-2028)
Figure 23. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Application (2017-2028)
Figure 24. Duchenne Muscular Dystrophy Average Selling Price (ASP) by Application (2017-2022) & (USD/Dose)
Figure 25. North America Duchenne Muscular Dystrophy Revenue 2017-2028 (US$ Million)
Figure 26. North America Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Figure 27. North America Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Figure 28. Asia-Pacific Duchenne Muscular Dystrophy Revenue 2017-2028 (US$ Million)
Figure 29. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share by Region (2017-2028)
Figure 30. Asia-Pacific Duchenne Muscular Dystrophy Revenue Market Share by Region (2017-2028)
Figure 31. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Figure 32. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Figure 33. Europe Duchenne Muscular Dystrophy Revenue Growth Rate 2017-2028 (US$ Million)
Figure 34. Europe Duchenne Muscular Dystrophy Sales Market Share by Country (2017-2028)
Figure 35. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2017-2028)
Figure 36. Europe Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Figure 37. Europe Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Figure 38. Latin America Duchenne Muscular Dystrophy Revenue Growth Rate 2017-2028 (US$ Million)
Figure 39. Latin America Duchenne Muscular Dystrophy Sales Market Share by Country (2017-2028)
Figure 40. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Country (2017-2022)
Figure 41. Latin America Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Figure 42. Latin America Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Figure 43. Middle East and Africa Duchenne Muscular Dystrophy Revenue Growth Rate 2017-2028 (US$ Million)
Figure 44. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2017-2028)
Figure 45. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Country (2017-2028)
Figure 46. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Type (2017-2022)
Figure 47. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Application (2017-2022)
Figure 48. Duchenne Muscular Dystrophy Supply Chain (Upstream and Downstream Market)
Figure 49. Global Production Market Share of Duchenne Muscular Dystrophy Raw Materials by Region in 2021
Figure 50. Duchenne Muscular Dystrophy Distribution Channels
Figure 51. Global Duchenne Muscular Dystrophy Percentage 2017-2028: Indirect Sales VS Direct Sales
Figure 52. Global Duchenne Muscular Dystrophy Percentage 2017-2028: Online Sales VS Offline Sales
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs